We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Oral Semaglutide
MedXY News
EnglishTag

Oral Semaglutide

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Oral Semaglutide and Cardiovascular Benefits in the SOUL Trial: Impact of Baseline and Changes in HbA1c and BMI on Clinical Outcomes
CardiologyBMIcardiovascular risk

Oral Semaglutide and Cardiovascular Benefits in the SOUL Trial: Impact of Baseline and Changes in HbA1c and BMI on Clinical Outcomes

By MedXY|Jul 22, 2026

This analysis of the SOUL trial shows oral semaglutide reduces major cardiovascular events, with greater benefits linked to higher baseline HbA1c and larger HbA1c reductions, while BMI changes did not significantly affect outcomes.

Oral Semaglutide and Cardiovascular Risk Factor Changes in High-Risk Type 2 Diabetes
CardiologyCardiovascular risk factors
Oral Semaglutide

Oral Semaglutide and Cardiovascular Risk Factor Changes in High-Risk Type 2 Diabetes

By MedXY|May 25, 2026

Oral semaglutide improved multiple cardiovascular risk factors in high-risk type 2 diabetes, including HbA1c, weight, systolic blood pressure, inflammation, and some lipid measures, with benefits sustained over nearly four years.

Orforglipron Demonstrates Superior HbA1c Reduction Over Oral Semaglutide in Type 2 Diabetes: Results from the ACHIEVE-3 Trial
Diabetes & EndocrinologyOral Semaglutideorforglipron

Orforglipron Demonstrates Superior HbA1c Reduction Over Oral Semaglutide in Type 2 Diabetes: Results from the ACHIEVE-3 Trial

By MedXY|Mar 6, 2026

The ACHIEVE-3 phase 3 trial demonstrates that orforglipron, a novel non-peptide oral GLP-1 receptor agonist, provides superior glycemic control compared to oral semaglutide in adults with type 2 diabetes, despite a higher frequency of gastr

Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial
Cardiologycardiovascular diseasechronic kidney disease

Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial

By MedXY|Feb 2, 2026

The SOUL trial demonstrates that oral semaglutide significantly slows the annual decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and cardiovascular disease, despite not meeting the primary composite k

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults
Diabetes & Endocrinologyclinical trialobesity

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults

By MedXY|Oct 8, 2025

Oral semaglutide 25 mg once daily significantly reduces body weight versus placebo and improves physical function in adults with overweight or obesity, offering an alternative to injectable formulations.

Oral Semaglutide Demonstrates Significant Weight Loss Efficacy in East Asian Adults with Overweight or Obesity: Insights from the OASIS 2 Trial
Diabetes & EndocrinologyOral Semaglutidetype 2 diabetes

Oral Semaglutide Demonstrates Significant Weight Loss Efficacy in East Asian Adults with Overweight or Obesity: Insights from the OASIS 2 Trial

By MedXY|Oct 6, 2025

The OASIS 2 trial shows oral semaglutide 50 mg significantly reduces body weight in East Asian adults with overweight or obesity, with or without type 2 diabetes, offering a promising therapeutic option with manageable safety profile.

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial
Cardiologycardiovascular outcomesOral Semaglutide

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

By MedXY|Oct 3, 2025

The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities